Drug Profile
Research programme: adenovirus-based cancer immunotherapeutics - Targovax
Alternative Names: ONCOS 401; ONCOS 802; ONCOS 902; ONCOS X02; ONCOS-402Latest Information Update: 17 Sep 2019
Price :
$50
*
At a glance
- Originator Oncos Therapeutics
- Developer Targovax
- Class Antineoplastics; Oncolytic viruses
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours